Clinical trials: Basal Cell Carcinoma of Skin
Carcinoma, Basal Cell (BCC)
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
This is a Phase 1, open-label, single-arm, multicenter study to assess the safety and tolerability of BSCT (anti-nf-P2X7) 10% Ointment in subjects with BCC.
- Trial name
- NCT02587819
- Testing
- Treatment with BSCT
- Volunteers
- 21 people
- Sponsor
- Biosceptre
Esophageal Cancer, Extrahepatic Bile Duct Cancer
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT00021047
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Skin Cancer Excision Site, Basal Cell Carcinoma
Impact of Dysport on PMFF Donor Scar
The purpose of this research study is to investigate the effect of pre-operative injections of Dysport (Abobotulinumtoxin-A, commonly known as "Botox") on the cosmetic appearance of and overall satisfaction with study…
- Conditions
- Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT07720726
- Testing
- Abobotulinumtoxin-A, Control- Saline injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Superficial Basal Cell Carcinoma
A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma
A patient decision aid (PDA) was tested in a population of patients with superficial basal cell carcinoma. This study evaluates whether the use of a PDA improved outcomes like decisional conflict and knowledge.
- Trial name
- NCT05628714
- Testing
- Patient decision aid for patients with superficial basal cell carcinoma
- Where
- Netherlands
- Volunteers
- 222 people
- Sponsor
- Maastricht University Medical Center
Merkel Cell Carcinoma, Basal Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer.
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Trial name
- ARTACUS (NCT04349436)
- Testing
- RP1, intra-tumoral injection, oncolytic virus
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Replimune, Inc.
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Basal Cell Carcinoma
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
To assess the feasibility and provide information on the utility of noninvasive line field confocal optical coherence tomography (LC-OCT) for the presurgical assessment of Mohs micrographic surgery sites in patients undergoing…
- Trial name
- NCT07182240
- Testing
- LC-OCT Imaging
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Roswell Park Cancer Institute
Basal Cell Carcinoma
Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions
The aim of this non-interventional study is to provide further data on the utilization, effectiveness, safety and clinical benefit including duration of response of Vismodegib for treatment of locally advanced basal cell…
- Trial name
- JONAS (NCT02781389)
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- University Hospital, Essen
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients This study is designed to evaluate whether a topical 5% niacinamide cream can help prevent skin cancer in organ…
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
- Trial name
- NCT07286318
- Testing
- Topical niacinamide 5% cream, Sunscreen
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Marissa Lobl
Melanoma (Skin), Nevus
Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms
A Multicenter, Prospective, Low-interventional Clinical Study Evaluating on mobile application validation ("ProRodinki") in assessing the risk of skin malignant neoplasms
- Conditions
- Melanoma (Skin), Nevus, Nevus, Spitz, Nevus Halo
- Trial name
- CAMELLIA (NCT05402046)
- Testing
- Mobile phone application "ProRodinki"
- Where
- 2 sites in Russia
- Volunteers
- 605 people
- Sponsor
- MelanomaPRO, Russia
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals